123 related articles for article (PubMed ID: 10168037)
1. Cost utility in second-line metastatic breast cancer.
Berdeaux G; Hurteloup P
Pharmacoeconomics; 1997 May; 11(5):492-7. PubMed ID: 10168037
[No Abstract] [Full Text] [Related]
2. Cost effectiveness of treatment options in advanced breast cancer in the UK.
Brown RE; Hutton J; Burrell A
Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
4. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
Launois R; Reboul-Marty J; Henry B; Bonneterre J
Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
[TBL] [Abstract][Full Text] [Related]
5. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
Launois RJ; Reboul-Marty JM; Bonneterre J
Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel and docetaxel. Innovation, but at what cost?
Lønning PE
Pharmacoeconomics; 1995 Jul; 8(1):1-4. PubMed ID: 10155597
[No Abstract] [Full Text] [Related]
7. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
Lamb HM; Wiseman LR
Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
[TBL] [Abstract][Full Text] [Related]
9. [Recent results of anticancer drugs acting on microtubules--navelbine, taxol and taxotere for the treatment of lung cancer].
Kawahara M; Furuse K
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2150-6. PubMed ID: 1359840
[No Abstract] [Full Text] [Related]
10. Introduction: taxoids and the management of breast cancer.
Hortobagyi GN
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-1-S13-2. PubMed ID: 9335510
[No Abstract] [Full Text] [Related]
11. [Treatment outcomes with vinorelbine for metastatic breast cancer patients previously treated with both doxorubicin and docetaxel].
Tashiro H; Sonoda K; Ohshiro T; Ohta M; Yamamura S; Ishikawa T; Itasaka H; Matsusaka T; Kume K
Gan To Kagaku Ryoho; 2001 Oct; 28(10):1397-401. PubMed ID: 11681247
[TBL] [Abstract][Full Text] [Related]
12. Progress in preclinical and clinical studies for the development of new anticancer drugs in Japan, with emphasis on taxanes.
Saijo N; Nishio K; Ohta S; Arioka H; Funayama Y; Fukuoka K; Kurokawa H; Nomoto T; Ishida T; Yamamoto N; Tamura T; Shinkai T; Eguchi K; Ohe Y; Kunito H; Ohtsu T; Sasaki Y
Cancer Chemother Pharmacol; 1996; 38 Suppl():S11-5. PubMed ID: 8765409
[No Abstract] [Full Text] [Related]
13. [From conquering metastatic disease to adjuvant therapy: clinical evolution of docetaxel in breast cancer].
Cartenì G
Tumori; 2001; 87(6):A1-5. PubMed ID: 11995695
[No Abstract] [Full Text] [Related]
14. The role of taxanes in the management of breast cancer.
Nabholtz JM
Semin Oncol; 1999 Jun; 26(3 Suppl 8):1-3. PubMed ID: 10403466
[No Abstract] [Full Text] [Related]
15. Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients.
Brown RE; Hutton J
Anticancer Drugs; 1998 Nov; 9(10):899-907. PubMed ID: 9890701
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
17. Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
Ibrahim NK; Sahin AA; Dubrow RA; Lynch PM; Boehnke-Michaud L; Valero V; Buzdar AU; Hortobagyi GN
Lancet; 2000 Jan; 355(9200):281-3. PubMed ID: 10675076
[TBL] [Abstract][Full Text] [Related]
18. [Vinorelbine in the treatment of non-small-cell lung cancer and breast cancer].
Kubota K
Gan To Kagaku Ryoho; 2000 Jul; 27(8):1301-6. PubMed ID: 10945030
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
